Glaukos Co. (NYSE:GKOS) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $156.17.

GKOS has been the topic of a number of research analyst reports. Needham & Company LLC increased their price target on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stifel Nicolaus raised their target price on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. Mizuho reduced their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Wells Fargo & Company raised their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, Truist Financial reduced their target price on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, April 11th.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently made changes to their positions in the company. Valeo Financial Advisors LLC boosted its stake in Glaukos by 1.5% in the 1st quarter. Valeo Financial Advisors LLC now owns 7,817 shares of the medical instruments supplier's stock valued at $769,000 after purchasing an additional 117 shares during the period. Capital Management Associates Inc bought a new position in Glaukos during the first quarter worth about $217,000. Principal Financial Group Inc. raised its stake in Glaukos by 21.8% in the 1st quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier's stock worth $32,187,000 after purchasing an additional 58,502 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after purchasing an additional 159 shares during the period. Finally, Illinois Municipal Retirement Fund grew its position in shares of Glaukos by 25.4% during the 1st quarter. Illinois Municipal Retirement Fund now owns 36,901 shares of the medical instruments supplier's stock worth $3,632,000 after purchasing an additional 7,483 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of NYSE:GKOS traded up $0.59 during trading on Tuesday, reaching $94.42. The stock had a trading volume of 1,382,542 shares, compared to its average volume of 652,161. The stock has a fifty day simple moving average of $99.10 and a two-hundred day simple moving average of $129.41. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 52 week low of $77.91 and a 52 week high of $163.71. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -32.90 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. During the same period in the prior year, the business earned ($0.70) EPS. The business's quarterly revenue was up 24.6% on a year-over-year basis. As a group, analysts anticipate that Glaukos will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.